Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires09:15 ET

Wall Street Stabilizes, Driving Quiet Premarket Action for US Equity Futures

MT Newswires09:09 ET

Sector Update: Health Care

MT Newswires08:56 ET

Pfizer's (PFE.US) new breast cancer drug Vepdegestrant research has mixed results, and Arvinas (ARVN.US) stock price plummeted by 40%.

Pfizer's next-generation breast cancer treatment drug vepdegestrant has achieved mixed results in its final phase of research, failing to delay cancer progression in all patients, but meeting the target for a subgroup of patients with specific genetic mutations.

Zhitong Finance08:21 ET

Express News | Arvinas Shares Drop 40.2%‍ Premarket After Co and Pfizer Report Late-Stage Data for Breast Cancer Treatment

Reuters07:27 ET

Arvinas And Pfizer Announced Topline Results From The Phase 3 VERITAC-2 Trial Of Vepdegestrant Monotherapy Versus Fulvestrant In Adults With Advanced Or Metastatic Breast Cancer

Benzinga06:48 ET